Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves new multiple myeloma drug elotuzumab

Elotuzumab (Empliciti, Bristol-Myers Squibb), a new immune-stimulating treatment for multiple myeloma (micrograph pictured) has been approved by the US Food and Drug Administration (FDA)

Source: Science Photo Library

The US Food and Drug Administration has approved three new drugs to treat multiple myeloma in the past few weeks

A new immune-stimulating treatment for multiple myeloma has been approved by the US Food and Drug Administration (FDA).

Elotuzumab (Empliciti; Bristol-Myers Squibb) was granted approval in combination with lenalidomide (Revlimid) and the corticosteroid dexamethasone for people who have already received one to three previous medications.

The drug works by activating the immune system to attack and kill multiple myeloma cells.

The FDA decision was based on results from a randomised, open-label clinical study of 646 participants whose multiple myeloma had returned after, or failed to respond to, prior treatment. Those taking elotuzumab plus lenalidomide and dexamethasone had a longer delay until their disease worsened than participants taking only lenalidomide and dexamethasone (19.4 months compared with 14.9 months).

Tumour shrinkage was observed in 78.5% of those taking elotuzumab plus lenalidomide and dexamethasone, versus 65.5% among those taking lenalidomide and dexamethasone.

“We are continuing to learn about the ways the immune system interacts with different types of cancer, including multiple myeloma,” says Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

Elotuzumab is the second monoclonal antibody that the FDA has approved to treat the disease, after daratumumab (Darzalex) was given the green light on 16 November 2015. Ixazomib (Ninlaro), the first oral proteasome inhibitor for multiple myeloma, was approved by the FDA on 20 November 2015.

The application for elotuzumab was given “breakthrough therapy” designation by the FDA, awarded when preliminary clinical evidence for a drug intended to treat a serious condition suggests it may demonstrate “substantial improvement” over available therapies. It was also granted orphan drug designation and priority review status.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200210

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Elotuzumab (Empliciti, Bristol-Myers Squibb), a new immune-stimulating treatment for multiple myeloma (micrograph pictured) has been approved by the US Food and Drug Administration (FDA)

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.